Latest Biotechnology News

Page 18 of 115
BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.
Ada Torres
Ada Torres
20 Aug 2026
Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.
Ada Torres
Ada Torres
19 Aug 2026
Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.
Ada Torres
Ada Torres
19 Aug 2026
Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.
Ada Torres
Ada Torres
17 Aug 2026
Avenira Ltd (ASX:AEV) is raising nearly $49 million through a heavily discounted three-for-two renounceable rights issue to finance the transition of its Wonarah Phosphate Project from development to production.
Maxwell Dee
Maxwell Dee
17 Aug 2026
Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
Ada Torres
13 Aug 2026
NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.
Ada Torres
Ada Torres
13 Aug 2026
Alterity Therapeutics has won a new US composition of matter patent for its lead drug ATH434, extending intellectual property protection to at least 2045 and boosting its commercial potential ahead of Phase 3 trials in Multiple System Atrophy.
Ada Torres
Ada Torres
12 Aug 2026
Starpharma has successfully completed a $32 million entitlement offer, nearly fully subscribed, to fund its DEP® HER2-Lutetium Phase 1 trial and further develop its oncology pipeline.
Ada Torres
Ada Torres
11 Aug 2026
Bio-Gene Technology has raised approximately A$3.275 million through its second tranche placement and share purchase plan underwriting, issuing over 51 million new shares and 69 million options to investors.
Ada Torres
Ada Torres
10 Aug 2026
ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.
Ada Torres
Ada Torres
10 Aug 2026
AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.
Ada Torres
Ada Torres
10 Aug 2026

Browse the archive

Full archive